Literature DB >> 15972296

Genomic structure and functional characterization of the human ADAM10 promoter.

Claudia Prinzen1, Ulrich Müller, Kristina Endres, Falk Fahrenholz, Rolf Postina.   

Abstract

The ADAM10 gene encodes a membrane-bound disintegrin-metalloproteinase, which, after overexpression in an Alzheimer disease (AD) mouse model, prevents amyloid pathology and improves long-term potentiation and memory. Because enhancing ADAM10 expression appears to be a reasonable approach for treatment of AD, we functionally analyzed the ADAM10 gene. Both human and mouse ADAM10 genes comprise approximately 160 kbp, are composed of 16 exons, and are evolutionarily highly conserved within 500 bp upstream of either translation initiation site. By using luciferase reporter assays, we demonstrate that nucleotides -2179 to -1 upstream of the human ADAM10 translation initiation site represent a functional TATA-less promoter. Within this region we identified and examined several single nucleotide polymorphisms, but did not detect significant differences in their appearance between AD and nondemented control subjects. By deletion analysis, site-directed mutagenesis, transcription factor overexpression and electrophoretic mobility shift assays, we identified nucleotides -508 to -300 as the core promoter and found Sp1, USF, and retinoic acid-responsive elements to modulate its activity. Finally, we identified vitamin A acid (RA) as an inducer of human ADAM10 promoter activity. This finding suggests that pharmacologic targeting of RA receptors may increase the expression of the alpha-secretase ADAM10 with beneficial effects on AD pathology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972296     DOI: 10.1096/fj.04-3619fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  42 in total

Review 1.  Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin.

Authors:  Johannes Prox; Andrea Rittger; Paul Saftig
Journal:  Exp Brain Res       Date:  2011-11-27       Impact factor: 1.972

Review 2.  Regulation of α-secretase ADAM10 expression and activity.

Authors:  Kristina Endres; Falk Fahrenholz
Journal:  Exp Brain Res       Date:  2011-10-04       Impact factor: 1.972

3.  Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease.

Authors:  L M Bekris; N M Galloway; S Millard; D Lockhart; G Li; D R Galasko; M R Farlow; C M Clark; J F Quinn; J A Kaye; G D Schellenberg; J B Leverenz; P Seubert; D W Tsuang; E R Peskind; C E Yu
Journal:  Neurobiol Aging       Date:  2010-12-31       Impact factor: 4.673

4.  Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5'-untranslated region.

Authors:  Sven Lammich; Dominik Buell; Sonja Zilow; Ann-Katrin Ludwig; Brigitte Nuscher; Stefan F Lichtenthaler; Claudia Prinzen; Falk Fahrenholz; Christian Haass
Journal:  J Biol Chem       Date:  2010-03-26       Impact factor: 5.157

5.  Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10.

Authors:  Johannes Prox; Michael Willenbrock; Silvio Weber; Tobias Lehmann; Dirk Schmidt-Arras; Ralf Schwanbeck; Paul Saftig; Michael Schwake
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

6.  Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli.

Authors:  Jürgen Schauber; Robert A Dorschner; Kenshi Yamasaki; Brook Brouha; Richard L Gallo
Journal:  Immunology       Date:  2006-08       Impact factor: 7.397

7.  Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer's disease.

Authors:  Rumana Akhter; Yvonne Shao; McKenzie Shaw; Shane Formica; Maria Khrestian; James B Leverenz; Lynn M Bekris
Journal:  Neurobiol Aging       Date:  2017-11-23       Impact factor: 4.673

Review 8.  All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease.

Authors:  Hyun-Pil Lee; Gemma Casadesus; Xiongwei Zhu; Hyoung-gon Lee; George Perry; Mark A Smith; Katarzyna Gustaw-Rothenberg; Alan Lerner
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

9.  Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.

Authors:  Mallory Gough; Catherine Parr-Sturgess; Edward Parkin
Journal:  Biochem Res Int       Date:  2010-09-30

Review 10.  Towards retinoid therapy for Alzheimer's disease.

Authors:  K Shudo; H Fukasawa; M Nakagomi; N Yamagata
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.